Michael D Kritzer1, Nicholas A Mischel2, Jonathan R Young3, Christopher S Lai4, Prakash S Masand5,6, Steven T Szabo7, Sanjay J Mathew8. 1. Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA. 2. Wayne State University, Detroit, Michigan, USA. 3. Duke University School of Medicine, Durham, North Carolina, USA. 4. Columbia University, New York, New York, USA. 5. CEO, Centers for Psychiatric Excellence (COPE), Adjunct Professor, New York, New York, USA. 6. Duke-NUS (National University of Singapore), Singapore. 7. Sunovion Pharmaceuticals, Chapel Hill, North Carolina, USA. 8. Baylor College of Medicine, Waco, Texas, USA.
Abstract
BACKGROUND: Mood disorders are a leading cause of morbidity. Many patients experience treatment-resistant depression (TRD), and suicide rates are rising. Faster-acting and more effective antidepressant medications are needed. Four decades of research has transformed the use of ketamine from an anesthetic to an outpatient treatment for major depressive disorder (MDD). Ketamine is a N-methyl-d-aspartate (NMDA) receptor antagonist and has been shown to rapidly improve mood symptoms and suicidal ideation by targeting the glutamate system directly. METHODS: We used the PubMed database to identify relevant articles published until September 1, 2020. We focused on meta-analyses, randomized controlled trials, and original observational studies. We included relevant studies for depression, MDD, TRD, bipolar disorder, anxiety, posttraumatic stress disorder (PTSD), suicide, ketamine, and esketamine. RESULTS: Both racemic ketamine and esketamine have been shown to rapidly treat depression and suicidality. There is evidence that ketamine can be helpful for anxiety and PTSD; however, more research is needed. Intranasal esketamine has been FDA approved to treat depression. CONCLUSIONS: This narrative review describes the evolution of ketamine to treat mood disorders and suicidality. We provide the evidence supporting recent developments using esketamine as well as unresolved issues in the field, such as dosing and safety.
BACKGROUND: Mood disorders are a leading cause of morbidity. Many patients experience treatment-resistant depression (TRD), and suicide rates are rising. Faster-acting and more effective antidepressant medications are needed. Four decades of research has transformed the use of ketamine from an anesthetic to an outpatient treatment for major depressive disorder (MDD). Ketamine is a N-methyl-d-aspartate (NMDA) receptor antagonist and has been shown to rapidly improve mood symptoms and suicidal ideation by targeting the glutamate system directly. METHODS: We used the PubMed database to identify relevant articles published until September 1, 2020. We focused on meta-analyses, randomized controlled trials, and original observational studies. We included relevant studies for depression, MDD, TRD, bipolar disorder, anxiety, posttraumatic stress disorder (PTSD), suicide, ketamine, and esketamine. RESULTS: Both racemic ketamine and esketamine have been shown to rapidly treat depression and suicidality. There is evidence that ketamine can be helpful for anxiety and PTSD; however, more research is needed. Intranasal esketamine has been FDA approved to treat depression. CONCLUSIONS: This narrative review describes the evolution of ketamine to treat mood disorders and suicidality. We provide the evidence supporting recent developments using esketamine as well as unresolved issues in the field, such as dosing and safety.
Authors: Carla M Canuso; Jaskaran B Singh; Maggie Fedgchin; Larry Alphs; Rosanne Lane; Pilar Lim; Christine Pinter; David Hough; Gerard Sanacora; Husseini Manji; Wayne C Drevets Journal: Am J Psychiatry Date: 2018-04-16 Impact factor: 18.112
Authors: Dawn F Ionescu; David A Luckenbaugh; Mark J Niciu; Erica M Richards; Carlos A Zarate Journal: Bipolar Disord Date: 2014-11-14 Impact factor: 6.744
Authors: Ella J Daly; Madhukar H Trivedi; Adam Janik; Honglan Li; Yun Zhang; Xiang Li; Rosanne Lane; Pilar Lim; Anna R Duca; David Hough; Michael E Thase; John Zajecka; Andrew Winokur; Ilona Divacka; Andrea Fagiolini; Wieslaw J Cubala; István Bitter; Pierre Blier; Richard C Shelton; Patricio Molero; Husseini Manji; Wayne C Drevets; Jaskaran B Singh Journal: JAMA Psychiatry Date: 2019-09-01 Impact factor: 21.596
Authors: Le-Ben Wan; Cara F Levitch; Andrew M Perez; Jess W Brallier; Dan V Iosifescu; Lee C Chang; Alexandra Foulkes; Sanjay J Mathew; Dennis S Charney; James W Murrough Journal: J Clin Psychiatry Date: 2015-03 Impact factor: 4.384
Authors: Mark J Niciu; Bridget J Shovestul; Brittany A Jaso; Cristan Farmer; David A Luckenbaugh; Nancy E Brutsche; Lawrence T Park; Elizabeth D Ballard; Carlos A Zarate Journal: J Affect Disord Date: 2018-02-17 Impact factor: 4.839
Authors: Paul Glue; Shona M Neehoff; Natalie J Medlicott; Andrew Gray; Guy Kibby; Neil McNaughton Journal: J Psychopharmacol Date: 2018-03-21 Impact factor: 4.153
Authors: Paulo R Shiroma; C Sophia Albott; Brian Johns; Paul Thuras; Joseph Wels; Kelvin O Lim Journal: Int J Neuropsychopharmacol Date: 2014-06-25 Impact factor: 5.176
Authors: André Rinaldi Fukushima; Pedro Enrique Navas-Suárez; Juliana Weckx Peña Muñoz; Esther Lopes Ricci; Luís Antônio Baffile Leoni; Érico C Caperuto; Leandro Yanase; Jeferson Santana; Elias de França; Jan Carlo Morais O Bertassoni Delorenzi; Alcides Felix Terrivel; Gláucio M Ferreira; Mario Hiroyuki Hirata; Lorena de Paula Pantaleon; Julia Zacarelli-Magalhães; Gabriel Ramos de Abreu; Paula A Faria Waziry; Maria Aparecida Nicoletti; Helenice de Souza Spinosa Journal: J Cardiovasc Dev Dis Date: 2022-09-07